Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q3 2013 · 10-Q
Revenue$2.78B$2.78B+14.7% vs Q3 2012 Net Income$789.00M$789.00M+16.8% vs Q3 2012 EPS Diluted$0.47$0.47+9.3% vs Q3 2012 Gross Profit$2,028,000,000+15.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Operating Cash Flowderived$753,096,000+1.0% Free Cash Flowderived$715,916,000+5.5% Margins · derivedGross margin72.9%+0.3 pt vs Q3 2012
Operating margin41.2%−1.8 pt vs Q3 2012
Net margin28.4%+0.5 pt vs Q3 2012
ended Sep 30, 2013 · filed Oct 31, 2013 · 31 d after period end